Contineum Therapeutics (NASDAQ:CTNM) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Contineum Therapeutics (NASDAQ:CTNM) from a hold rating to a sell rating in a research report report published on Saturday.

Other research analysts have also issued reports about the company. Royal Bank Of Canada dropped their price objective on Contineum Therapeutics from $25.00 to $22.00 and set an “outperform” rating for the company in a research note on Friday, November 21st. Leerink Partners started coverage on shares of Contineum Therapeutics in a research report on Thursday, November 13th. They set an “outperform” rating and a $22.00 target price for the company. Robert W. Baird cut their price target on shares of Contineum Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Monday, November 24th. Morgan Stanley restated an “equal weight” rating and issued a $14.00 price target (down from $23.00) on shares of Contineum Therapeutics in a research report on Thursday, January 8th. Finally, Leerink Partnrs raised shares of Contineum Therapeutics to a “strong-buy” rating in a report on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $19.00.

Contineum Therapeutics Stock Down 1.5%

Shares of CTNM opened at $9.17 on Friday. The company has a 50-day moving average price of $11.21 and a two-hundred day moving average price of $9.66. The stock has a market cap of $267.58 million, a price-to-earnings ratio of -4.08 and a beta of 1.21. Contineum Therapeutics has a 12 month low of $3.35 and a 12 month high of $13.56.

Contineum Therapeutics (NASDAQ:CTNM) last issued its earnings results on Thursday, October 30th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.13. Equities research analysts expect that Contineum Therapeutics will post -2.01 EPS for the current fiscal year.

Institutional Trading of Contineum Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CTNM. Strs Ohio bought a new stake in Contineum Therapeutics in the first quarter valued at about $27,000. Qube Research & Technologies Ltd bought a new position in Contineum Therapeutics during the second quarter worth about $43,000. Marex Group plc acquired a new position in shares of Contineum Therapeutics during the 2nd quarter worth about $45,000. Bridgeway Capital Management LLC bought a new stake in shares of Contineum Therapeutics in the 2nd quarter valued at about $76,000. Finally, Jane Street Group LLC acquired a new stake in shares of Contineum Therapeutics in the 2nd quarter valued at approximately $81,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.